Cyclomedica

Cyclomedica is a leader in nuclear medicine and molecular imaging, focusing on advanced functional lung imaging technologies. Established in the 1980s, the company’s flagship product, Technegas®, is a radiopharmaceutical used for diagnosing pulmonary embolism and other respiratory conditions. This innovative product combines carbon nanoparticles with radioactive isotopes to enhance lung imaging, facilitating early intervention and better patient management. The company aims to improve the quality of life for respiratory patients worldwide through early diagnosis and enhanced care. Cyclomedica operates under principles of innovation, empowerment, and leadership in health solutions. Its product range includes variations of Technegas®, such as Pertechnegas and Galligas, which expand its clinical applications in respiratory medicine. The company also develops state-of-the-art medical equipment and supports research initiatives to explore new clinical uses. Cyclomedica serves healthcare providers, hospitals, and nuclear medicine specialists, focusing on improving diagnostic accuracy and patient outcomes in respiratory disease management. As part of Cyclopharm Limited, Cyclomedica is positioned for growth in the molecular imaging sector.

• Employees 72
• Founded 1986
• Annual Revenue $25736000
• Total Funding $30000000